- Home
- AQST vs NYXH Comparison
AQST vs NYXH Comparison
Compare AQST & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- NYXH
- Stock Information
- Founded
- AQST 2004
- NYXH 2009
- Country
- AQST United States
- NYXH Belgium
- Employees
- AQST N/A
- NYXH N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- AQST Health Care
- NYXH Health Care
- Exchange
- AQST Nasdaq
- NYXH Nasdaq
- Market Cap
- AQST 272.9M
- NYXH 222.3M
- IPO Year
- AQST 2018
- NYXH 2021
- Fundamental
- Price
- AQST $2.71
- NYXH $7.65
- Analyst Decision
- AQST Strong Buy
- NYXH Strong Buy
- Analyst Count
- AQST 5
- NYXH 4
- Target Price
- AQST $11.40
- NYXH $14.50
- AVG Volume (30 Days)
- AQST 1.7M
- NYXH 151.3K
- Earning Date
- AQST 05-12-2025
- NYXH 05-14-2025
- Dividend Yield
- AQST N/A
- NYXH N/A
- EPS Growth
- AQST N/A
- NYXH N/A
- EPS
- AQST N/A
- NYXH N/A
- Revenue
- AQST $54,228,000.00
- NYXH $4,716,818.00
- Revenue This Year
- AQST N/A
- NYXH $323.07
- Revenue Next Year
- AQST $40.62
- NYXH $204.30
- P/E Ratio
- AQST N/A
- NYXH N/A
- Revenue Growth
- AQST 5.29
- NYXH N/A
- 52 Week Low
- AQST $2.12
- NYXH $5.55
- 52 Week High
- AQST $5.80
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- AQST 54.01
- NYXH 59.27
- Support Level
- AQST $2.22
- NYXH $7.59
- Resistance Level
- AQST $2.79
- NYXH $7.96
- Average True Range (ATR)
- AQST 0.19
- NYXH 0.51
- MACD
- AQST 0.04
- NYXH 0.16
- Stochastic Oscillator
- AQST 75.64
- NYXH 67.22
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.